



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07C 59/135, 69/736, 235/32, 259/04, A61K 31/165, 31/19, A61P 3/10, 5/16	A1	(11) International Publication Number: WO 00/07972 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/IB99/01447 (22) International Filing Date: 4 August 1999 (04.08.99) (30) Priority Data: 9816935.2 5 August 1998 (05.08.98) GB (71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): APELQVIST, Theresa [SE/SE]; Sägstuvägen 2B, 3 tr, S-141 49 Huddinge (SE). GOEDE, Patrick [SE/SE]; Passvagen 45, S-147 53 Tumba (SE). HOLMGREN, Erik [SE/SE]; Vitmossevägen 40, S-134 43 Gustavsberg (SE). (74) Agents: BANNERMAN, D., G. et al.; Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS (I) (57) Abstract Novel glucocorticoid and thyroid receptor ligands as provided which have the general formula (I) in which: R₁ is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, or cyano, or a pharmaceutically acceptable salt thereof. R₂ and R₃ are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R₂ and R₃ being other than hydrogen. X is carbonyl or methylene. R₄ is an aliphatic, aromatic, or heteroaromatic. Y is hydroxyl, methoxy, amino, or alkyl amino. n is an integer from 0 to 4. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a glucocorticoid or thyroid receptor gene (such as diabetes, hypercholesterolemia, or obesity) using these compounds is also disclosed.		